Research-use peptides
A neutral, dated status list for peptides people commonly discuss. None of these is an FDA-approved medicine, and several are under FDA compounding review as of July 2026 — under review is not approval. We make no health claim about any of them; this is here so you can keep an accurate record. Informational only, not medical advice.
Where these stand
These are generally sold through unregulated channels, often behind a "for research use only" label — which is a legal disclaimer, not a safety review (see peptide safety & source review). Their compounding status is actively changing: an FDA advisory committee is reviewing several of them in July 2026. A review is a discussion-and-public-comment step, not a decision — no outcome is stated here, and being "under review" is not approval.
Neutral status by compound
Identity and regulatory/evidence status only — no doses, no protocols, no sourcing. Dates reflect a fast-moving picture; check fda.gov for the current status.
| Compound | Status (neutral, dated) |
|---|---|
| BPC-157 | Synthetic peptide fragment. Not FDA-approved; evidence is largely from animal studies. Its pharmacy-compounding status is under FDA review as of July 2026 — under review is not approval. |
| TB-500 (thymosin β-4 fragment) | Not FDA-approved. Published human studies used full-length thymosin β-4; human data on the TB-500 fragment specifically is very limited. Under FDA compounding review as of July 2026. |
| GHK-Cu | Copper-binding tripeptide, mainly used as a topical cosmetic ingredient. Injectable/systemic forms marketed for a condition would be unapproved. |
| CJC-1295 | Synthetic growth-hormone-releasing hormone analog. Not FDA-approved; the FDA has noted reported increased heart rate / vasodilatory reaction with limited data. |
| Ipamorelin | Growth-hormone-secretagogue peptide. Not FDA-approved. |
| Sermorelin | Was sold as the approved product Geref, later discontinued — the FDA determined it was not withdrawn for safety or effectiveness reasons. There is no currently marketed FDA-approved sermorelin product. |
| MOTS-c | Mitochondrial-derived peptide, studied mainly in animal models. Not FDA-approved. Under FDA compounding review as of July 2026. |
| KPV | Short peptide fragment studied for anti-inflammatory activity, largely preclinical. Not FDA-approved. Under FDA compounding review as of July 2026. |
| Semax | Peptide registered for use in some other countries (per secondary sources); not FDA-approved and without completed Western trials. Under FDA compounding review as of July 2026. |
| Epitalon | Synthetic tetrapeptide marketed for anti-aging; no published human randomized trial. Not FDA-approved. Under FDA compounding review as of July 2026. |
| Retatrutide | Investigational triple-hormone-receptor agonist still in clinical trials (per ClinicalTrials.gov). Not FDA-approved and not lawfully compounded; available only through registered trials. |
A precision note
These peptides are not DEA-scheduled controlled substances, so "controlled" or "banned drug" is the wrong label. But "not scheduled" is not the same as approved, safe, or unregulated — most remain unapproved new drugs in the FDA's framework. For athletes and Service Members, many are prohibited in sport (see the sport & duty note).
Keep your own record. If you track one of these, add it as a custom peptide item in the planner with its source status and storage note, and review the list with a clinician. See also the peptides overview.
Common questions
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved medicine. Its evidence is largely from animal studies, and its status in pharmacy compounding is under FDA review as of July 2026 — being under review is not approval. The FDA has also noted safety considerations such as immunogenicity and limited human data.
Did the FDA make these peptides legal in 2026?
No. FDA's public compounding notices reflect that several peptides were taken off a restricted 'Category 2' list after their nominations were withdrawn — which is not the same as approval, and they were not moved onto the 'under-evaluation' list. A separate FDA advisory committee is reviewing several peptides in July 2026; that's a discussion step, not a decision, and no outcome is recorded here.
Does SuppSafety sell or tell me how to use these?
No. SuppSafety makes no health claim about any of these compounds and provides no dosing, reconstitution, injection, cycling, or sourcing guidance. You can track a peptide as a custom item to keep your own record and review it with a clinician.